China Pioneer Pharma Holdings Limited
Sembol: 1345.HK
HKSE
1.42
HKDBugünkü piyasa fiyatı
13.7445
F/K Oranı
0.0000
PEG Oranı
1.67B
MRK Kapağı
- 0.04%
DIV Verimi
China Pioneer Pharma Holdings Limited (1345-HK) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 0 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 0 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 0 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 0 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | -40.4 | -176.4 | -210.8 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | 0 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | 0 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 19 | 225.4 | 39.4 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 0 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 0 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 0 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 0 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 0 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 0 | 145.7 | 235.3 | 142.6 |
Sıkça Sorulan Sorular
Nedir China Pioneer Pharma Holdings Limited (1345.HK) toplam varlıklar?
China Pioneer Pharma Holdings Limited (1345.HK) toplam varlıklar 1530905000.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir N/A'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.427'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -0.127'dur.
İşletme net kar marjı nedir?
Net kâr marjı 0.093'dir.
Firma toplam geliri nedir?
Toplam gelir 0.085'dur.
Nedir China Pioneer Pharma Holdings Limited (1345.HK) net kar (net gelir)?
Net kar (net gelir) 145718000.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 74020000.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 488030000.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 0.000'tir.